DTL
CASC

Dynamic Technology Lab’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Dynamic Technology Lab’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,512
Closed -$47K – 1332
2015
Q4 		$47K Buy
3,512
+1,766
+101% +$30.4K 0.01% 838
2015
Q3 		$29K Buy
+1,746
New +$35.8K 0.01% 776
2014
Q3 		– Sell
-2,495
Closed -$48K – 969
2014
Q2 		$48K Buy
+2,495
New +$44K 0.02% 633

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dynamic Technology Lab's CASC Position: Q1 2016 in Review

Dynamic Technology Lab sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2016, closing a stake of 3,512 shares — an estimated $47K sold.

Dynamic Technology Lab first reported a position in CASC in Q2 2014 and held it in 3 quarters. The position peaked at $48K in Q2 2014. 80 funds tracked by Wall St. Rank hold CASC as of Q1 2016.

  • Dynamic Technology Lab reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Dynamic Technology Lab sold 3,512 Cascadian Therapeutics, Inc. shares in Q1 2016, an estimated $47K.
  • Dynamic Technology Lab first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 3 quarters.
  • Dynamic Technology Lab's Cascadian Therapeutics, Inc. position peaked at $48K in Q2 2014.
  • 80 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2016.

Based on Dynamic Technology Lab's 13F filing for Q1 2016, filed 18 May 2016.